SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- September 26, 2006 -- Theravance, Inc. (NASDAQ: THRX) today announced that detailed results from ATLAS 1 and ATLAS 2, its telavancin Phase 3 studies for the treatment of complicated skin and skin structure infections (cSSSI), have been accepted for presentation at the Third International Symposium on Resistant Gram-Positive Infections in Niagara-on-the-Lake, Ontario, Canada from October 9 - 11 and at the 44th Annual Meeting of the Infectious Disease Society of America (IDSA) in Toronto, Ontario, Canada from October 12 - 15. Dr. G. Ralph Corey, Professor of Medicine and Infectious Diseases, Duke University Medical Center, will present the data at both conferences.
